Joining us today is Dr. Shankar Musunuri, the co-founder, chairman, and CEO of Ocugen, Inc., a biotechnology company that develops vaccines for public health and gene and cell therapies to treat eye diseases. Dr. Musunuri brings over 30 years of experience to the Ocugen team. Prior to co-founding Ocugen, he held senior leadership roles at several companies, and spent nearly 15 years at Pfizer. In this interview, Dr. Musunuri discusses some of Ocugen’s innovative advances. Their first product, a modifier gene therapy platform, is currently undergoing Phase I trials. Ocugen’s second program will reach clinics next year and targets age-related macular degeneration, which affects nine to 10 million Americans.
The Philadelphia Eagles haven’t always been a premier franchise in the NFL. After years of…
By MICHAEL RUBINKAM Associated Press A large staffing firm that performed COVID-19 contact tracing for…
By FARNOUSH AMIRI Associated Press The House passed legislation Wednesday that would establish a broader…
The Philadelphia Phillies took the field in the early afternoon for their final game in…
Whether you're a fan of the cult classic franchise or not, there are still a…
Looking for some fun and unique things to do in Philly this weekend? We've got…
This website uses cookies.